Derrick C. Li appointed as Chief Business Officer effective February 9, 2026, to lead business development, financing, licensing, and partnerships.13
Nelson Sun's role expanded to Chief Operating Officer while retaining Chief Financial Officer responsibilities, effective February 9, 2026.13
Appointments announced on February 12, 2026, coinciding with ARD-101 Phase 3 development for hyperphagia in Prader-Willi Syndrome, with topline data expected Q3 2026, and ARD-201 in Phase 2 for obesity.3
Aardvark Therapeutics (Nasdaq:
AARD) focuses on small-molecule therapeutics for metabolic diseases.3
Sources:
1. https://stockhouse.com/news/press-releases/2026/02/12/aardvark-therapeutics-announces-leadership-appointments
3. https://www.stocktitan.net/news/AARD/aardvark-therapeutics-announces-leadership-hhrmzonvm731.html